All In Biotech

Drug Trial Radar · NCT02454712

Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)

A Phase 1, Single-Center, Dose-Escalation Study to Determine the Safety and Pharmacokinetics of a Single Oral Dose of PF614 in Healthy Subjects Compared to OxyContin®

Last checked: Nov 19, 2026Latest source record: Oct 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Nov 16, 2016

Primary completion

Jan 18, 2018

Study completion Jan 18, 2018

Sponsor

Lead sponsor
Ensysce BiosciencesIndustry
Sponsor type
Industry
Collaborators
PRA Health Sciences
First posted
May 27, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

PF614 is an oxycodone prodrug that is designed for extended-release of oxycodone comparable to OxyContin. This Single Ascending Dose (SAD) study is designed to assess the safety and pharmacokinetics (PK) of PF614 in comparison to standard doses of OxyContin.

Conditions

  • Healthy

Interventions

  • PF614Drug

    PF614 is an oxycodone prodrug

  • Oxycodone extended-releaseDrug

    Oxycodone extended-release is the comparator drug

  • Naltrexone HydrochlorideDrug

    Naltrexone HCl tablets, 50 mg, will be used to block high dose opioid effects in healthy volunteers

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SafetyTime frame: 30 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PRA Health Sciences - Early Development Services

    Lenexa, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.